The Plasma Protein Therapeutics Association (PPTA) is a dynamic trade association representing a unique sector of the biologics and biotechnology industry. With over 1,000 human plasma collection centers in North America and Europe, PPTA also represents the manufacturers of lifesaving plasma protein therapies. These therapies, known as plasma protein therapies, are used to treat a variety of rare diseases and serious medical conditions in small patient populations worldwide.

PPTA works globally to advocate for patient access to plasma-derived medicines, improve the availability of plasma, and advance the understanding of the plasma ecosystem. In addition to advocacy, PPTA administers standards and programs to ensure the quality and safety of plasma collection and manufacturing, protecting both donors and patients. The association also collaborates with patient advocacy organizations and engages in constructive dialogue with regulatory agencies.

PPTA's mission is to advocate for patient access to plasma protein therapies, advance the understanding of the plasma ecosystem, and responsibly improve the reliable availability of plasma. With a focus on patient well-being and donor safety, PPTA is committed to driving progressive policies for plasma collections and ensuring broad and reliable access to plasma-derived medicinal products